Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis

Blöchl-Daum, Brigitte; Müller, Markus; Meisinger, V; Eichler, H.-G.; Fassolt, A; Pehamberger, Hubert

doi:10.1038/bjc.1996.164

Cited by 66 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other than new optical methods and costly imaging methods with radioactive tags, minimally invasive methods with site specificity are very limited, the most commonly reported method being microdialysis, which invokes implantation of a needle into the tissue to sample the extracellular fluid through a semi-permeable membrane. 64 Despite its inherent invasiveness and other problems, 65 microdialysis has been developed in recent years as an in situ method of measurement for research applications. However, its invasiveness and slow response render microdialysis impractical for clinical management of treatments such as photodynamic therapy (PDT).…”

Section: Clinical Applications Of Optical Spectroscopy For Cancer Thementioning

confidence: 99%

Spectrroscopic Sensing of Cancer and Cancer Therapy: Current Status of Translational Research

Bigio

Bown²

2004

Cancer Biology & Therapy

143

View full text Add to dashboard Cite

Various types of optical spectroscopy have been investigated as methods to effect a non-invasive, real-time in-situ assessment of tissue pathology. All of these methods have one basic principle in common: the optical spectrum of a tissue contains information about the biochemical composition and/or the structure of the tissue, and that information conveys diagnostic information. The biochemical information can be obtained by measuring absorption, fluorescence, or Raman scattering signals. Structural and morphological information may be obtained by techniques that assess the elastic-scattering properties of tissue. These basic approaches are useful for the detection of cancer as well as for other diagnostic applications such as hemoglobin saturation, intra-luminal detection of atherosclerosis, and simply the identification of different tissue types during procedures. Optical spectroscopic measurements can also be employed in the management of disease treatment. The site-specific pharmacokinetics of chemotherapy and photodynamic therapy agents can be used to customize dosage to the patient, and diagnostic spectroscopy can be used to monitor response to treatment. In recent years clinical studies have provided indications of potential efficacy, and some of these modalities are now entering a translational research stage, with an eye to approval and commercialization. A benefit of these methods is their inherent low cost and ease of implementation, generally mediated with small portable instruments, not requiring any specialized facilities, and eventually not requiring expert interpretation. This paper reviews briefly the most common methods of diagnostic optical spectroscopy, and reviews in greater depth recent clinical translational research invoking scattering spectroscopy as the enabling technology, which has been the experience of the authors.

show abstract

Section: Clinical Applications Of Optical Spectroscopy For Cancer Thementioning

confidence: 99%

Spectrroscopic Sensing of Cancer and Cancer Therapy: Current Status of Translational Research

Bigio

Bown²

2004

Cancer Biology & Therapy

143

View full text Add to dashboard Cite

show abstract

“…Microdialysis studies were done to evaluate the tumor ECF disposition of nonliposomal CKD-602 and released CKD-602 from S-CKD602 (1,4,5,19). After administration of S-CKD602, microdialysis studies (n = 3-4 mice per interval) were obtained every 20 min from 0 to 2 h and every 30 min from 24 to 27 h, 48 to 51 h, and 72 to 75 h. After administration of nonliposomal CKD-602, microdialysis studies (n = 3-4 mice per interval) were obtained every 20 min from 0 to 2 h and every 30 min from 4 to 7 h and 20 to 24 h. Microdialysis probe recovery was estimated by retrodialysis calibration from 0 to 2 h after administration of S-CKD602 and nonliposomal CKD-602 as previously described (19).…”

Section: Methodsmentioning

confidence: 99%

“…Microdialysis is an in vivo sampling technique used to study the pharmacokinetics and drug metabolism in the blood and ECF of various tissues and tumors (1,4,5,19). The use of microdialysis methods to evaluate the disposition of anticancer agents in tumors is relatively new.…”

mentioning

confidence: 99%

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

Zamboni

Strychor

Joseph

et al. 2007

Clinical Cancer Research

108

View full text Add to dashboard Cite

Purpose: S-CKD602 is a STEALTH liposomal formulation of CKD-602, a camptothecin analogue. The cytotoxicity of camptothecin analogues is related to the duration of exposure in the tumor. STEALTH liposomal formulations contain lipid conjugated to methoxypolyethylene glycol and have been designed to prolong drug circulation time, increase tumor delivery, and improve the therapeutic index. For STEALTH liposomal formulations of anticancer agents to achieve antitumor effects, the active drug must be released into the tumor extracellular fluid (ECF). Experimental Design: S-CKD602 at 1 mg/kg or nonliposomal CKD-602 at 30 mg/kg was administered once via tail vein to mice bearing A375 human melanoma xenografts. Mice (n = 3 per time point) were euthanized at 0.083 to 24 h, 48 h, and 72 h after S-CKD02 and from 0.083 to 24 h after nonliposomal CKD-602. Plasma samples were processed to measure encapsulated, released, and sum total (encapsulated plus released) CKD-602, and tumor and tissue samples were processed to measure sum total CKD-602. Microdialysis samples of tumor ECF were obtained from 0 to 2 h, 4 to 7 h, and 20 to 24 h after nonliposomal CKD-602 and from 0 to 2 h, 24 to 27 h, 48 to 51 h, and 72 to 75 h after S-CKD602. A liquid chromatographymass spectrometry assay was used to measure the total (sum of lactone and hydroxyl acid) CKD-602. The area under the concentration-versus-time curves (AUC) from 0 to infinity and time >1ng/mL in tumor were estimated.Results: For S-CKD602, the CKD-602 sum total AUC in plasma and tumor and the CKD-602 AUC in tumor ECF were 201,929, 13,194, and 187 ng/mL h, respectively. For S-CKD602, 82% of CKD-602 remains encapsulated in plasma. For nonliposomal CKD-602, the CKD-602 AUC in plasma and tumor and the CKD-602 AUC in tumor ECF were 9,117, 11,661, and 639 ng/mL Á h, respectively. The duration of time the CKD-602 concentration was >1ng/mL in tumor ECF after S-CKD602 and nonliposomal CKD-602 was >72 and f20 h, respectively. For S-CKD602, the CKD-602 sum total exposure was 1.3-fold higher in fat as compared with muscle. The ratio of CKD-602 sum total exposure in fat to muscle was 3.8-fold higher after administration of S-CKD602 compared with nonliposomal CKD-602. Conclusion: S-CKD602 provides pharmacokinetic advantages in plasma, tumor, and tumor ECF compared with nonliposomal CKD-602 at 1/30th of the dose, which is consistent with the improved antitumor efficacy of S-CKD602 in preclinical studies. The distribution of S-CKD602 is greater in fat compared with muscle whereas the distribution of nonliposomal CKD-602 is greater in muscle compared with fat.These results suggest that the body composition of a patient may affect the disposition of S-CKD602 and released CKD-602.

show abstract

“…By evaluation of the area under the curve of the tumor/tissue ratio for a series of antineoplastic drugs in preclinical investigations, the best candidate for further drug development can be identified. An example is related to malignant melanoma [61,62] , where e.g. carboplatin and dacarbazine concentrations have been measured in cutaneous metastases of human malignant melanomas and the penetration characteristics of the drugs have been evaluated.…”

Section: In Clinical Researchmentioning

confidence: 99%

Microdialysis Sampling for Investigations of Bioavailability and Bioequivalence of Topically Administered Drugs: Current State and Future Perspectives

Holmgaard

Nielsen

Benfeldt

2010

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Microdialysis (MD) in the skin is a unique technique for in vivo sampling of topically as well as systemically administered drugs at the site of action, e.g. sampling the unbound tissue concentrations in the dermis and subcutaneous tissue. MD as a research method has undergone significant development, improvement and validation during the last decade and has proved to be a versatile, safe and valuable tool for pharmacokinetic and pharmacodynamic studies. This review gives an overview of the current state and future perspectives of dermal MD sampling. Methodological issues such as choice of instrumentation, calibration and experimental procedures are discussed along with the analytical considerations necessary for successful sampling. Clinical MD studies in the skin are reviewed with emphasis on pharmacokinetic studies of topically applied drugs with or without impairment of skin barrier function by skin disease or barrier perturbation. A comparison between MD and other tissue sampling techniques reveals the advantages and limitations of the method. Subsequently, an in-depth discussion of the application of MD for the evaluation of bioavailability and bioequivalence of topical formulations is concluded by the current regulatory point of view. The future perspective includes further expansion and validation of the use of MD in the experimental and clinical setting as well as in the optimization of the method for regulatory purposes, i.e. the commercialization of bioequivalent, generic drug products.

show abstract

Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis

Cited by 66 publications

References 16 publications

Spectrroscopic Sensing of Cancer and Cancer Therapy: Current Status of Translational Research

Spectrroscopic Sensing of Cancer and Cancer Therapy: Current Status of Translational Research

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

Microdialysis Sampling for Investigations of Bioavailability and Bioequivalence of Topically Administered Drugs: Current State and Future Perspectives

Contact Info

Product

Resources

About